SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Druker Brian J.)
 

Search: WFRF:(Druker Brian J.) > Efficacy of imatini...

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.

Kantarjian, Hagop M (author)
Larson, Richard A (author)
Guilhot, Francois (author)
show more...
O'Brien, Stephen G (author)
Mone, Manisha (author)
Rudoltz, Marc (author)
Krahnke, Tillmann (author)
Cortes, Jorge (author)
Druker, Brian J (author)
Wadenvik, Hans, 1955 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
show less...
 (creator_code:org_t)
Wiley, 2009
2009
English.
In: Cancer. - : Wiley. - 0008-543X .- 1097-0142. ; 115:3, s. 551-60
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Imatinib mesylate given orally at a daily dose of 400 mg is the standard of care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). Treatment guidelines propose dose escalation based on clinical assessments of disease response.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Keyword

Benzamides
Clinical Trials as Topic
Disease-Free Survival
Drug Administration Schedule
Leukemia
Myeloid
Chronic-Phase
drug therapy
Piperazines
administration & dosage
Pyrimidines
administration & dosage
Survival Analysis
Treatment Outcome

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Cancer (Search for host publication in LIBRIS)

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view